Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts

Vincenzo Esposito, Alessandra Verdina, Lucrezia Manente, Enrico P. Spugnini, Rosaria Viglietti, Roberto Parrella, Pasquale Pagliano, Giovanni Parrella, Rossella Galati, Antonio De Luca, Alfonso Baldi, Vincenzo Montesarchio, Antonio Chirianni

Research output: Contribution to journalArticle

Abstract

The introduction of HAART (highly-active-antiretroviral-therapy) has resulted in extended survival of HIV positive patients. Conversely, due to the prolonged expectancy of life and the ageing of the HIV positive population, tumors are now one of the major cause of death, and among them hepatocellular carcinoma (HCC) has become a growing concern in these patients. Considering the potential anti-tumoral effects of HIV protease inhibitors, we decided to evaluate the anti-tumoral activity of Amprenavir on liver carcinoma and to evaluate its potential synergistic effects in combination with standard chemoterapic drugs, such as Doxorubicin. Our results indicate that Amprenavir had direct inhibitory effects on invasion of Huh-7 hepatocarcinoma cell lines, inhibiting MMP proteolytic activation. Amprenavir was able to delay the growth of hepatocarcinoma xenografts in nude mice and had a synergistic effect with Doxorubicin. Furthermore, Amprenavir was able to promote regression of hepatocarcinoma growth in vivo by anti-angiogenetic and overall anti-tumor activities, independently by PI3K/AKT related pathways that at today is one of the more suggestive hypothesis to explain the anti-tumor effects of the different protease inhibitors. In summary these findings suggest novel anti-neoplastic action of Amprenavir on liver cancer showing the possibility of novel combination therapies.

Original languageEnglish
Pages (from-to)640-645
Number of pages6
JournalJournal of Cellular Physiology
Volume228
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Heterografts
Tumors
Growth
Liver
Doxorubicin
HIV
HIV Protease Inhibitors
Neoplasms
Highly Active Antiretroviral Therapy
Liver Neoplasms
Life Expectancy
Protease Inhibitors
Matrix Metalloproteinases
Phosphatidylinositol 3-Kinases
Nude Mice
Cause of Death
Hepatocellular Carcinoma
Aging of materials
Chemical activation
Cells

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology
  • Physiology

Cite this

Esposito, V., Verdina, A., Manente, L., Spugnini, E. P., Viglietti, R., Parrella, R., ... Chirianni, A. (2013). Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. Journal of Cellular Physiology, 228(3), 640-645. https://doi.org/10.1002/jcp.24173

Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. / Esposito, Vincenzo; Verdina, Alessandra; Manente, Lucrezia; Spugnini, Enrico P.; Viglietti, Rosaria; Parrella, Roberto; Pagliano, Pasquale; Parrella, Giovanni; Galati, Rossella; De Luca, Antonio; Baldi, Alfonso; Montesarchio, Vincenzo; Chirianni, Antonio.

In: Journal of Cellular Physiology, Vol. 228, No. 3, 03.2013, p. 640-645.

Research output: Contribution to journalArticle

Esposito, V, Verdina, A, Manente, L, Spugnini, EP, Viglietti, R, Parrella, R, Pagliano, P, Parrella, G, Galati, R, De Luca, A, Baldi, A, Montesarchio, V & Chirianni, A 2013, 'Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts', Journal of Cellular Physiology, vol. 228, no. 3, pp. 640-645. https://doi.org/10.1002/jcp.24173
Esposito V, Verdina A, Manente L, Spugnini EP, Viglietti R, Parrella R et al. Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. Journal of Cellular Physiology. 2013 Mar;228(3):640-645. https://doi.org/10.1002/jcp.24173
Esposito, Vincenzo ; Verdina, Alessandra ; Manente, Lucrezia ; Spugnini, Enrico P. ; Viglietti, Rosaria ; Parrella, Roberto ; Pagliano, Pasquale ; Parrella, Giovanni ; Galati, Rossella ; De Luca, Antonio ; Baldi, Alfonso ; Montesarchio, Vincenzo ; Chirianni, Antonio. / Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts. In: Journal of Cellular Physiology. 2013 ; Vol. 228, No. 3. pp. 640-645.
@article{13b4feac84bd47dc971d1f3f09889ae6,
title = "Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts",
abstract = "The introduction of HAART (highly-active-antiretroviral-therapy) has resulted in extended survival of HIV positive patients. Conversely, due to the prolonged expectancy of life and the ageing of the HIV positive population, tumors are now one of the major cause of death, and among them hepatocellular carcinoma (HCC) has become a growing concern in these patients. Considering the potential anti-tumoral effects of HIV protease inhibitors, we decided to evaluate the anti-tumoral activity of Amprenavir on liver carcinoma and to evaluate its potential synergistic effects in combination with standard chemoterapic drugs, such as Doxorubicin. Our results indicate that Amprenavir had direct inhibitory effects on invasion of Huh-7 hepatocarcinoma cell lines, inhibiting MMP proteolytic activation. Amprenavir was able to delay the growth of hepatocarcinoma xenografts in nude mice and had a synergistic effect with Doxorubicin. Furthermore, Amprenavir was able to promote regression of hepatocarcinoma growth in vivo by anti-angiogenetic and overall anti-tumor activities, independently by PI3K/AKT related pathways that at today is one of the more suggestive hypothesis to explain the anti-tumor effects of the different protease inhibitors. In summary these findings suggest novel anti-neoplastic action of Amprenavir on liver cancer showing the possibility of novel combination therapies.",
author = "Vincenzo Esposito and Alessandra Verdina and Lucrezia Manente and Spugnini, {Enrico P.} and Rosaria Viglietti and Roberto Parrella and Pasquale Pagliano and Giovanni Parrella and Rossella Galati and {De Luca}, Antonio and Alfonso Baldi and Vincenzo Montesarchio and Antonio Chirianni",
year = "2013",
month = "3",
doi = "10.1002/jcp.24173",
language = "English",
volume = "228",
pages = "640--645",
journal = "Journal of cellular and comparative physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Amprenavir inhibits the migration in human hepatocarcinoma cell and the growth of xenografts

AU - Esposito, Vincenzo

AU - Verdina, Alessandra

AU - Manente, Lucrezia

AU - Spugnini, Enrico P.

AU - Viglietti, Rosaria

AU - Parrella, Roberto

AU - Pagliano, Pasquale

AU - Parrella, Giovanni

AU - Galati, Rossella

AU - De Luca, Antonio

AU - Baldi, Alfonso

AU - Montesarchio, Vincenzo

AU - Chirianni, Antonio

PY - 2013/3

Y1 - 2013/3

N2 - The introduction of HAART (highly-active-antiretroviral-therapy) has resulted in extended survival of HIV positive patients. Conversely, due to the prolonged expectancy of life and the ageing of the HIV positive population, tumors are now one of the major cause of death, and among them hepatocellular carcinoma (HCC) has become a growing concern in these patients. Considering the potential anti-tumoral effects of HIV protease inhibitors, we decided to evaluate the anti-tumoral activity of Amprenavir on liver carcinoma and to evaluate its potential synergistic effects in combination with standard chemoterapic drugs, such as Doxorubicin. Our results indicate that Amprenavir had direct inhibitory effects on invasion of Huh-7 hepatocarcinoma cell lines, inhibiting MMP proteolytic activation. Amprenavir was able to delay the growth of hepatocarcinoma xenografts in nude mice and had a synergistic effect with Doxorubicin. Furthermore, Amprenavir was able to promote regression of hepatocarcinoma growth in vivo by anti-angiogenetic and overall anti-tumor activities, independently by PI3K/AKT related pathways that at today is one of the more suggestive hypothesis to explain the anti-tumor effects of the different protease inhibitors. In summary these findings suggest novel anti-neoplastic action of Amprenavir on liver cancer showing the possibility of novel combination therapies.

AB - The introduction of HAART (highly-active-antiretroviral-therapy) has resulted in extended survival of HIV positive patients. Conversely, due to the prolonged expectancy of life and the ageing of the HIV positive population, tumors are now one of the major cause of death, and among them hepatocellular carcinoma (HCC) has become a growing concern in these patients. Considering the potential anti-tumoral effects of HIV protease inhibitors, we decided to evaluate the anti-tumoral activity of Amprenavir on liver carcinoma and to evaluate its potential synergistic effects in combination with standard chemoterapic drugs, such as Doxorubicin. Our results indicate that Amprenavir had direct inhibitory effects on invasion of Huh-7 hepatocarcinoma cell lines, inhibiting MMP proteolytic activation. Amprenavir was able to delay the growth of hepatocarcinoma xenografts in nude mice and had a synergistic effect with Doxorubicin. Furthermore, Amprenavir was able to promote regression of hepatocarcinoma growth in vivo by anti-angiogenetic and overall anti-tumor activities, independently by PI3K/AKT related pathways that at today is one of the more suggestive hypothesis to explain the anti-tumor effects of the different protease inhibitors. In summary these findings suggest novel anti-neoplastic action of Amprenavir on liver cancer showing the possibility of novel combination therapies.

UR - http://www.scopus.com/inward/record.url?scp=84870475903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870475903&partnerID=8YFLogxK

U2 - 10.1002/jcp.24173

DO - 10.1002/jcp.24173

M3 - Article

C2 - 22886568

AN - SCOPUS:84870475903

VL - 228

SP - 640

EP - 645

JO - Journal of cellular and comparative physiology

JF - Journal of cellular and comparative physiology

SN - 0021-9541

IS - 3

ER -